Unacknowledged Casualties — Transparency and Sources
About This Site
What this site is, what it is based on, how it uses evidence, and who is responsible for the claims it makes.
This page exists because the credibility of this site depends on transparency — about its sources, its evidential standards, its limitations, and the people whose work it draws on. Journalists, researchers, lawyers, and policymakers are encouraged to read it before drawing on this site’s content.
What This Site Is
This site — Unacknowledged Casualties: The ADF Quinoline Drug Trials and the Families Left Behind — is a public-interest research site based on a comprehensive research report of the same title, prepared in 2026 for investigative, policy, and advocacy purposes.
The report synthesises peer-reviewed scientific literature, regulatory agency documentation, Australian Senate inquiry submissions, coronial inquest records, veteran advocacy evidence, domestic violence research, neuropsychiatric literature, and neurotoxicology sources. It incorporates the findings of the Royal Commission into Defence and Veteran Suicide (Final Report, September 2024) and the Australian Government response (December 2024).
The site is designed to make this material accessible to journalists, policymakers, affected families, and the general public. It presents the evidence clearly, identifies where it is strong and where it is incomplete, and supports the case for the institutional responses described in the What You Can Do section.
What This Site Is Not
Four things this site does not do — stated plainly, because the distinction between what is claimed and what is not claimed matters for how this evidence is used.
This site does not provide medical advice, does not diagnose any individual, and is not a substitute for clinical assessment by a qualified practitioner.
This site does not provide legal advice. Nothing on this site constitutes legal counsel. Individuals with legal questions should consult a qualified lawyer.
This site does not assert that mefloquine or tafenoquine caused any specific act of domestic violence or any specific family outcome in any individual case. It documents a plausible mechanism and a documented pattern. Individual causation requires individual assessment.
This site does not represent DVA, the Department of Defence, or any government agency. It is an independent public-interest publication. Its conclusions are those of its authors, not of any official body.
This site uses four evidential registers throughout. They are identified at the foot of relevant sections on each page. They reflect a commitment to transparency about the strength of the evidence being presented — because the difference between what is proven, what is plausible, and what is uncertain is not a minor distinction.
Established Fact
Findings confirmed by peer-reviewed science, regulatory agency determinations, or official parliamentary, coronial, or governmental records. These are the most robust claims on this site and can be verified against publicly available primary sources. The FDA black box warning, the product data sheet adverse event listings, and the Royal Commission findings are examples.
Plausible Mechanism
A biological or clinical pathway consistent with the scientific literature, providing a credible explanation for an observed or proposed phenomenon, but not yet demonstrated by a direct study in the specific ADF veteran and family population. The proposed link between quinoline-induced limbic injury and elevated domestic violence risk is a plausible mechanism — a serious hypothesis warranting investigation, not a proven finding.
Documented Case Evidence
Cases or patterns recorded in advocacy submissions, parliamentary testimony, or media records. These are accurately represented as sourced from identified materials, but have not been independently verified by this site. Readers relying on specific figures or case details for legal or formal purposes should consult the primary sources directly.
Area of Uncertainty
Questions that the current evidence does not resolve, presented honestly rather than minimised. The most significant area of uncertainty on this site is the absence of a direct study measuring domestic violence rates in the ADF quinoline cohort. That gap is identified consistently throughout as a research priority, not papered over.
Source Transparency
Two figures are central to the Australian evidence base drawn on throughout this report and this site. Their standing — as both evidence sources and advocates — is disclosed here in full. This disclosure is made not to discredit their work, but because readers are entitled to weigh it with complete information.
Major Stuart McCarthy
QVFA Senate Submission 94 — Primary institutional sourceMajor Stuart McCarthy prepared Senate Submission 94 on behalf of the Quinoline Veterans and Families Association. It is the primary source for much of the Australian-specific institutional and factual detail on this site — the dosing figures, the coronial omissions, the DVA incentive structure, the details of the tafenoquine trial cohort, and the documented pattern of official responses.
Major McCarthy is himself an affected ADF veteran and has been a sustained public advocate for quinoline veterans and their families for many years. His submission is detailed, internally consistent, and supported by cross-references to publicly available documentation. Readers should be aware of his standing as both a witness and an advocate when weighing his evidence. Where his specific figures are relied upon for formal or legal purposes, verification against primary AMI and DVA records is recommended.
Professor Jane Quinn
Senate Submission 73 — Scientific and neurotoxicological sourceProfessor Jane Quinn of Charles Sturt University prepared Senate Submission 73. She is a neurotoxicologist whose peer-reviewed work on quinoline toxicity — including a 2015 paper in the Journal of Parasitology Research — is cited in the independent scientific literature.
Professor Quinn also has personal experience of mefloquine-related harm within her own family. Her scientific expertise and her personal history are both relevant to her evidence. This dual standing is disclosed here so that readers can weigh her contributions with that context in view.
The underlying neurotoxicology drawn on by both McCarthy and Quinn is independently established in the international peer-reviewed literature, including work by Nevin, Ritchie, and others not connected to the ADF advocacy context. However, the Australian-specific advocacy submissions and the peer-reviewed Australian papers are not wholly independent of one another. This site acknowledges that relationship wherever it is relevant and recommends that readers consult the international literature independently where the scientific foundation of a claim is important to them.
The Causation Framing
This report does not claim that quinoline toxicity is the sole cause of domestic violence in affected ADF families, nor that it is necessarily the primary cause.
The most defensible reading of the evidence is that the harm experienced by spouses and children is overdetermined — that quinoline-induced neurological injury, combat-related trauma, the documented culture of militarised masculinity within the ADF, and the failure of the institutional response each contribute, and that they compound one another.
The strongest peer-reviewed Australian study of intimate partner violence in ADF families (Pollard and Ferguson, 2020) attributes the problem to cultural and structural factors and does not address drug toxicity at all. This site argues that quinoline neurotoxicity is a serious, under-investigated contributor that the responsible institutions have failed to examine. It does not argue that it displaces the other causes.
Where the evidence permits only an inference rather than a demonstrated causal chain, this is stated explicitly. The distinction between what is proven, what is plausible, and what remains uncertain is not rhetorical — it is the difference between responsible advocacy and overclaiming that invites dismissal.
This site consistently frames harm to the veteran without attribution of moral blame. Neurologically injured individuals are not morally responsible for pharmacologically induced behavioural changes they did not choose and were not warned about. The harm documented throughout this site is systemic in origin. Acknowledging the harm to partners and children does not require — and this site does not engage in — characterising affected veterans as perpetrators in the ordinary moral sense. The veteran is also a casualty of the institutional decisions documented here. Recognising all parties simultaneously is the only accurate account of what happened.
A Note on the Royal Commission Updates
This site was prepared in 2026 and incorporates findings from the Royal Commission into Defence and Veteran Suicide (Final Report, September 2024) and the Australian Government response (December 2024). These developments postdate most of the primary source material — the Senate submissions, the peer-reviewed literature, and the advocacy record — on which the underlying research report draws.
Where the Royal Commission’s findings or the government’s response have materially changed the institutional landscape described in the report, this is noted explicitly on the relevant pages. The Royal Commission’s acceptance in principle of a brain injury program for veterans is the most significant such development. Its limitations — particularly the absence of any extension to families — are noted wherever relevant.
The flat claim that the system offers no recognition of quinoline-related brain injury is no longer accurate as stated. The recommendations of this site should therefore be read as building on, and seeking to extend, the Royal Commission’s findings — not as describing a complete vacuum in which nothing has been acknowledged.
Key Sources
The following sources have been drawn upon in the preparation of the report on which this site is based. Full citations appear throughout the site pages. Primary sources are listed here for reference and for readers wishing to verify specific claims independently.
Australian Senate and Parliamentary Sources
- McCarthy, S. (QVFA). Submission 94: Use of the Quinoline Anti-Malarial Drugs Mefloquine and Tafenoquine in the Australian Defence Force. Foreign Affairs, Defence and Trade References Committee, 2018.
- Quinn, Dr Jane C. Submission 73: Mefloquine toxicity: implications for serving personnel and veterans of the Australian Defence Force. Senate Foreign Affairs, Defence and Trade References Committee.
- Royal Commission into Defence and Veteran Suicide. Final Report, Volume 4, Chapter 22. September 2024.
- Australian Government Response to the Royal Commission into Defence and Veteran Suicide. December 2024.
Regulatory Agency Documents
- US FDA. Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. 2013.
- US FDA. Product label information — mefloquine hydrochloride. 2013.
- Therapeutic Goods Administration. Database of Adverse Event Notifications (DAEN): mefloquine and tafenoquine entries.
- Australian mefloquine product data sheet. F.H. La Roche / Roche Products Pty Ltd, PIL.4158, 2014.
- UK MHRA. Drug Safety Update: Mefloquine — strengthened warnings on neuropsychiatric side effects.
Peer-Reviewed and Medical Literature
- Ritchie, E.C., Block, J., and Nevin, R.L. (2013). Psychiatric side effects of mefloquine: applications to forensic psychiatry. Journal of the American Academy of Psychiatry and the Law, 41(2), 224–235.
- Nevin, R.L. (2014). Idiosyncratic quinoline central nervous system toxicity. International Journal for Parasitology: Drugs and Drug Resistance, 4(2), 118–125.
- Nevin, R.L., and Ritchie, E.C. (2016). The mefloquine intoxication syndrome. In Post-Traumatic Stress Disorder and Related Diseases in Combat Veterans. Springer International.
- Quinn, J.C. (2015). Complex membrane channel blockade. Journal of Parasitology Research.
- McCarthy, S. (2015). Malaria prevention, mefloquine neurotoxicity, neuropsychiatric illness, and risk-benefit analysis in the Australian Defence Force. Journal of Parasitology Research.
- Dow, G., et al. (2006). Mefloquine induces dose-related neurological effects in a rat model. Antimicrobial Agents and Chemotherapy, 50(3), 1045–1053.
- Agboruche, R., et al. (2009). In-vitro toxicity assessment of antimalarial drugs on cultured embryonic rat neurons. WRAIR Research.
Developmental and Trauma Research
- Felitti, V.J., et al. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. American Journal of Preventive Medicine, 14(4), 245–258.
- Kitzmann, K.M., et al. (2003). Child witnesses to domestic violence: a meta-analytic review. Journal of Consulting and Clinical Psychology, 71(2), 339–352.
- Main, M., and Hesse, E. (1990). Parents’ unresolved traumatic experiences are related to infant disorganized attachment status. In Attachment in the Preschool Years. University of Chicago Press.
- Liotti, G. (2004). Trauma, dissociation, and disorganized attachment. Psychotherapy: Theory, Research, Practice, Training, 41(4), 472–486.
Domestic Violence and Military Research
- Epidemiological reviews of intimate partner violence in returning veteran populations. Epidemiological Reviews, Oxford University Press, 2015.
- Research on post-deployment reintegration, substance abuse, and family violence in combat veterans. ScienceDirect, multiple sources.
- Pollard, J.A., and Ferguson, M. (2020). Intimate partner violence in ADF families: cultural and structural contributors.
- US Army and CDC review of Fort Bragg homicides, 2002. Subsequent forensic psychiatric commentary by Nevin and Ritchie.
DVA Framework Documents
- Repatriation Medical Authority Statements of Principles: relevant SOPs for depressive disorder, anxiety disorders, bipolar disorder, psychotic disorder, and insomnia linked to quinoline antimalarial exposure.
- DVA Non-Liability Healthcare (NLHC) program documentation.
- DVA Health Provider guidance on mental health liability assessment.
- Veterans’ Entitlements, Treatment and Support (Simplification and Harmonisation) Act 2025 (VETS Act).
Contact
This site was prepared as part of an investigative research project examining the ADF antimalarial drug trials of 1998–2002. It is intended for research, advocacy, and policy purposes.
For background briefings, source guidance, media enquiries, or further information, please contact via jacqualineroche.com/contact.
This site does not represent DVA, the Department of Defence, or any government agency. It is an independent public-interest publication. Responses to media enquiries are provided on a best-efforts basis.